VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Monday, January 5, 2026
Stock Comparison
Euronext N.V. vs Novo Nordisk A/S
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Euronext N.V.
ENX · Euronext Paris
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Euronext N.V.'s moat claims, evidence, and risks.
View ENX analysisNovo Nordisk A/S
NOVOB · Nasdaq Copenhagen
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Novo Nordisk A/S's moat claims, evidence, and risks.
View NOVOB analysisComparison highlights
- Moat score gap: Novo Nordisk A/S leads (85 / 100 vs 74 / 100 for Euronext N.V.).
- Segment focus: Euronext N.V. has 7 segments (34.4% in Trading); Novo Nordisk A/S has 3 segments (71.1% in Diabetes care).
- Moat breadth: Euronext N.V. has 7 moat types across 4 domains; Novo Nordisk A/S has 5 across 3.
Primary market context
Euronext N.V.
Trading
Multi-asset exchange trading venues (cash equities, derivatives, fixed income, FX, power)
Europe (with global participants)
Broker-dealers, banks, proprietary trading firms, asset managers, and other market participants
Trading venue operator
34.4%
Novo Nordisk A/S
Diabetes care
Diabetes pharmaceuticals (GLP-1 for type 2 diabetes, insulin, and related therapies)
Global
Payers/providers and patients (via wholesalers/pharmacies/hospitals)
Originator pharma (R&D, regulatory, manufacturing, commercialization)
71.1%
Side-by-side metrics
Moat coverage
Shared moat types
Euronext N.V. strengths
Novo Nordisk A/S strengths
Segment mix
Euronext N.V. segments
Full profile >Listing
Oligopoly
Trading
Oligopoly
Advanced Data Services
Quasi-Monopoly
Clearing
Oligopoly
Custody & Settlement
Quasi-Monopoly
Technology Solutions & Other
Competitive
Investor Services
Competitive
Novo Nordisk A/S segments
Full profile >Diabetes care
Oligopoly
Obesity care
Duopoly
Rare disease
Oligopoly
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.